Updates are available Correction dated 2020-10-26

Article History

Received: 15 July 2020

Revised: 2 September 2020

Accepted: 3 September 2020

First Online: 16 September 2020

Change Date: 27 February 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00415-020-10255-1

Compliance with ethical standards

:

: Dr. Comella serves on the editorial board of Clinical Neuropharmacology and Sleep Medicine. She receives compensation/honoraria for services as a consultant or an advisory committee member: Acorda Therapeutics, Allergan, Inc; Lundbeck Ltd.; Merz Pharmaceuticals; Acadia Pharmaceuticals; Ipsen Pharmaceuticals, Jazz. Pharmaceuticals, Neurocrine Biosciences Inc., Revance Therapeutic, Sunovion., AEON Biopharma. She receives royalties from Cambridge University Press and Wolters Kluwer. She receives research support from the Parkinson’s Disease Foundation. Joaquim J. Ferreira has held consultancy functions with GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, Abbott, Abbvie, BIAL, Merck-Serono, Merz, Ipsen, Biogen, NeuroDerm, Zambon, Sunovion, Affiris, ONO; has received lecture fees from Biogen and BIAL, Sunovion, ONO, Zambon, Abbvie; has received grants from GlaxoSmithKline, Grunenthal, MSD, Allergan, Novartis, Fundação MSD (Portugal), Medtronic and Teva; has been employed by Faculdade de Medicina de Lisboa and CNS—Campus Neurológico Sénior. Marion Azoulai and Emilie Pain are employed by Carenity who received funding from Ipsen for conducting this survey. Savary Om was an Ipsen employee at the time of study.

: Clinical Research Ethics Committee or Independent Review Board approval was not required for this exploratory patient satisfaction survey.

: All respondents provided informed consent to participate.